Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma

BACKGROUND: Tazemetostat is a selective and orally available inhibitor of enhancer of zeste homolog 2 (EZH2), a histone methyltransferase and epigenetic regulator of cellular differentiation programs. We carried out a phase I study of tazemetostat in Japanese patients with relapsed or refractory B‐c...

Descripción completa

Detalles Bibliográficos
Autores principales: Munakata, Wataru, Shirasugi, Yukari, Tobinai, Kensei, Onizuka, Makoto, Makita, Shinichi, Suzuki, Rikio, Maruyama, Dai, Kawai, Hidetsugu, Izutsu, Koji, Nakanishi, Tadashi, Shiba, Sari, Hojo, Seichiro, Ando, Kiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935786/
https://www.ncbi.nlm.nih.gov/pubmed/33492746
http://dx.doi.org/10.1111/cas.14822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935786/
https://www.ncbi.nlm.nih.gov/pubmed/33492746
http://dx.doi.org/10.1111/cas.14822

Ejemplares similares